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Abstract 
Background: Bacterial resistance to antibiotics is increasing worldwide. Antibiotic-resistant strains can lead to seri-
ous problems regarding treatment of infection. Carbapenem antibiotics are the final treatment option for infections 
caused by serious and life-threatening multidrug-resistant gram-negative bacteria. Therefore, an understanding of 
carbapenem resistance is important for infection control. In the study described herein, the phenotypic and geno-
typic features of carbapenem-resistant Enterobacteriaceae strains isolated in our hospital were evaluated.
Methods: In total, 43 carbapenem-resistant strains were included in this study. Sensitivity to antibiotics was deter-
mined using the VITEK®2 system. The modified Hodge test (MHT) and metallo-β-lactamase (MBL) antimicrobial 
gradient test were performed for phenotypic identification. Resistance genes IMP, VIM, KPC, NDM-1, and OXA-48 were 
amplified by multiplex PCR.
Results: The OXA-48 gene was detected in seven strains, and the NDM-1 gene in one strain. No resistance genes 
were detected in the remainder of strains. A significant correlation was observed between the MHT test and OXA-48 
positivity, and between the MBL antimicrobial gradient test and positivity for resistance genes (p < 0.05).
Conclusion: The finding of one NDM-1-positive isolate in this study indicates that carbapenem resistance is spread-
ing in Turkey. Carbapenem resistance spreads rapidly and causes challenges in treatment, and results in high mortal-
ity/morbidity rates. Therefore, is necessary to determine carbapenem resistance in Enterobacteriaceae isolates and to 
take essential infection control precautions to avoid spread of this resistance.
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Metallo-β-lactamase antimicrobial gradient test
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Background
The increase in antibiotic resistance in the Enterobac-
teriaceae family has become a major threat to public 
health. Especially in recent years, Enterobacteriaceae 
family members have been identified as important noso-
comial pathogens; infection can lead to severe morbidity 
and mortality, particularly in intensive care units (ICU), 
internal medicine and surgical units, and pediatric units 
[1].
Within the Enterobacteriaceae family, carbapenem-
resistant Klebsiella pneumoniae strains have recently 
been noted in many parts of the world [2, 3]. Carbap-
enemase, an enzyme belonging to the K. pneumoniae 
carbapenemase (KPC) gene family, causes resistance by 
breaking down carbapenems. This enzyme was first iso-
lated from a K. pneumoniae strain in 1996 and is included 
in the Ambler classification of β-lactamases. Although 
KPC β-lactamases are mostly found in K. pneumoniae, 
they can also be found in Enterobacter and Salmonella 
species. While metallo-β-lactamase (MBL) enzymes 
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(which belong to Ambler class B) are frequently observed 
in non-fermentative bacteria, they can also be found in 
enteric bacteria. The most frequently described MBLs are 
Verona integron encoded metallo-β-lactamase (VIM), 
imipenem-hydrolyzing β-lactamase (IMI), Seoul imipen-
emase (SIM), and German imipenemase (GIM) enzymes.
The Clinical and Laboratory Standards Institute (CLSI) 
has increased the minimum inhibitory concentration 
(MIC) value or reduced the disk diffusion zones and rec-
ommended confirmation of carbapenemase production 
by the modified Hodge test (MHT) of Enterobacteriaceae 
in order to facilitate the detection of Enterobacteriaceae 
[4].
While resistance of chromosomal-mediated (intrin-
sic) carbapenemases is limited, some plasmid-mediated 
carbapenemases have emerged in recent years. These 
enzymes have primarily been described in Klebsiella spp. 
and Serratia marcescens, and throughout different coun-
tries [5, 6]. Plasmid-mediated (extrinsic) carbapenemases 
can hydrolyse other β-lactam antibiotics in addition to 
carbapenems. These are the members of Ambler class A, 
B and D β-lactamases. The SME, NMC, IMI, KPC, and 
GES enzymes comprise class A carbapenemases. More-
over, IPM, VIM, GIM, SPM, SIM, and NDM-1 enzymes 
comprise class B, and OXA enzymes that hydrolyse oxa-
cillins comprise class D [7].
In Turkey, resistance mediated by KPC and New Delhi 
metallo-β-lactamase (NDM-1) enzymes in gram-negative 
enteric bacilli have been reported [8, 9]. Class D OXA 
carbapenemase-mediated carbapenem resistance has 
also been observed among gram-negative enteric bacilli 
in the context of nosocomial infections.
However, there are a limited number of studies related 
to carbapenem resistance mechanisms. In the study 
described herein, the characteristics of phenotypic 
and genotypic resistance of the carbapenem-resistant 
Enterobacteriaceae (Escherichia coli and Klebsiella spp.) 
strains isolated from patients in our hospital were evalu-
ated. The clinical importance of this resistance was also 
determined.
Methods
Our study was conducted on isolates derived from the 
following clinical samples: blood, rectal swab, urine, 
peritoneal fluid, sputum, tracheal aspirate, wounds, bron-
choalveolar lavage (BAL) and pleural fluid, etc. Samples 
were isolated from patients in intensive care, internal 
intensive care, the surgical clinic, the internal medicine 
clinic, and the bone marrow transplantation (BMT) unit 
at Istanbul Bilim University Europe Florence Nightin-
gale Hospital between January 7th 2012 to January 7th 
2013, and subsequently transferred to the microbiol-
ogy laboratory. The experiments were conducted on 43 
carbapenem-resistant Enterobactericeae isolates. Only 
one strain from each patient was included in the study. 
Enterobactericeae strains were detected as carbapenem-
resistant by using the VITEK®2 automated system (bio-
Mérieux, France). Bacterial suspensions were stored in 
freezing tubes including beads at −40 °C. Sensitivities to 
IMP (imipenem), MEM (meropenem) and ERT (ertap-
enem) were confirmed by the antimicrobial gradient test 
in collected isolates. Carbapenemase production was 
determined by the MHT. Metallo-β-lactamase (MBL) 
production was evaluated using IMP and IMP/EDTA 
antimicrobial gradient test strips (E-test, bioMérieux, 
France). When the rate of IMP/IMP  +  EDTA was ≥8, 
isolates considered MBL-positive. When the rate of IMP/
IMP + EDTA was <8, isolates were considered MBL-neg-
ative [10].
Multiplex PCR (Hyplex® SuperBug ID, Germany) 
was used to search for genes affecting carbapenemase 
production. DNA extraction was conducted using the 
AxyPrep Microbial DNA Isolation Kit (Axygen Bio-
sciences, USA) that lysed microorganisms by heat-
ing, use of detergents and mechanical techniques. The 
Hyplex® SuperBug ID system was used to detect VIM, 
IPM, NDM-1, OXA-48, and KPC. No additional control 
strains were used.
Mean, standard deviation, minimum–maximum, rate, 
and frequency values were used to determine statisti-
cal significance. A kappa test was used for compliance 
analysis. The SPSS 22.0 program was used for statistical 
analyses.
Results
A total of 43 patients were registered for the study, whose 
mean age was 53.8 (range 3–86). 28 (65.1 %) were male 
and 15 (34.9 %) male.
Of 43 strains, 38 were K. pneumoniae (88.4  %), four 
were E. coli (9.3  %), and one was K. oxytoca (2.3  %). 
According to antimicrobial gradient test and VITEK®2 
test results, the greatest resistance to these 43 isolates 
was to ERT among the carbapenems (97.7 and 100  %, 
respectively), followed by MEM (93 and 90.7  % resist-
ance, respectively) and IMP (79.1 and 88.4 % resistance, 
respectively).
Forty percent of these patients were followed up in 
the internal ICU, 36  % were followed up in the surgery 
ICU, 12 % were followed up in the BMT unit, and 12 % 
were followed up in the internal medicine unit. Of these 
25 patients, bacterial growth was observed in blood 
cultures (eight patients), respiratory isolates (six), rec-
tal swabs (five), urine cultures (three), wound cultures 
(two), and peritoneal fluid culture (one). Additionally, 
19 of 43 patients had a history of stem cell-solid organ 
transplantation.
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According to the MHT, of 43 strains, 35 (85  %) were 
carbapenemase-positive. According to MBL antimicro-
bial gradient test results, only two were MBL-positive 
(4.7 %).
Seven of the isolates (16.3  %) were positive for the 
OXA-48 gene, as determined by multiplex PCR. The 
NDM-1 gene was detected only in one strain (2.3  %). 
VIM, IPM and KPC resistance genes were not detected in 
any isolate (Table 1).
There was no significant correlation between OXA-
48 resistance gene positivity and the ERT antimicrobial 
gradient test, MEM antimicrobial gradient test or IMP 
antimicrobial gradient test, nor was there a correlation 
between OXA-48 resistance gene positivity and ERT 
VITEK®2 or MEM VITEK®2 results (p > 0.05). Addition-
ally, no correlation was detected between OXA-48 resist-
ance gene positivity and IMP VITEK®2 results (Table 2).
A correlation was observed between OXA-48 resist-
ance gene positivity and MHT positivity (p =  0.004). A 
significant relationship between the MBL antimicrobial 
gradient test and NDM-1 was also observed (p = 0.000) 
(Table 3).
Discussion
Carbapenem antibiotics are the last treatment option 
for severe, life-threatening infections caused by gram 
negative enteric bacilli with multiple drug resistance. 
Therefore, an understanding of carbapenem resistance 
is important. The emergence of resistant strains, as well 
as those with the potential to become resistant, can differ 
according to geographical region.
The source of microorganisms leading to hospital out-
breaks and determination of the transmission path, as 
well as the identification of control methods, create a 
basis for epidemiological studies. Rapid identification of 
strains is important whether or not there is an outbreak 
and provides crucial information regarding the control 
of hospital outbreaks. Antibiotic susceptibility tests have 
become fundamental tools in the identification of many 
hospital outbreaks due to their common usage. Moreo-
ver, these tests are standardized and can be applied to 
many other factors. However, as for other phenotypic 
methods, antibiotic susceptibility profiles are not ideal 
because they can be affected by growth medium, phase 
of reproduction and rate of spontaneous mutations. 
Therefore, genotyping techniques are preferentially used 
worldwide. With regard to determining the relationship 
between bacterial isolates, the techniques of serotyping, 
biotyping, antibiotyping, and bacteriophage typing have 
been replaced by others, including plasmid analysis and 
PCR-based typing methods, such as ribotyping [11].
In Turkey, molecular studies focusing on carbapenem 
resistance mechanisms are limited [8, 12]. Some regional 
studies have shown an association between the OXA-48 
gene and carbapenem resistance in gram-negative enteric 
bacilli [13, 14]. It was recently reported that carbapenem 
resistance may be associated with certain situations, such 
as being transferred between hospitals or from long-term 
care centers, stay in the ICU, the presence of a central 
venous catheter, usage of antibiotics, and having diabe-
tes mellitus [15, 16]. In this study, 27 of 43 patients were 
monitored in the ICU. Since our hospital was the refer-
ence hospital for units such as cardiovascular surgery 
and transplantation of stem cells and solid organs, most 
of our patients had follow-up or hospitalization histories 
prior to being admitted to our hospital.
In our study, of 43 patients infected with carbapenem-
resistant Enterobacteriaceae strains, 25 patients died 
(58.1 %). Patel et al. [2] demonstrated that the mortality 
rates of carbapenem-resistant K. pneumoniae infected 
Table 1 Results of  multiplex PCR for  carbapenem-resist-
ance genes in Enterobacteriaceae isolates
Genes Positive Negative
n % n %
OXA-48 7 16.3 36 83.7
VIM 0 0.0 43 100.0
IPM 0 0.0 43 100.0
NDM-1 1 2.3 42 97.7
KPC 0 0.0 43 100.0
Table 2 Relationship between susceptibility to carbapenems and OXA-48 gene positivity
ERT ertapenem, MEM meropenem, IMP imipenem, S sensitive, R resistance
Antibiotics E-TEST and OXA-48 VITEK® 2 and OXA-48
Positive Negative p Positive Negative p
S R S R S R S R
ERT 7 0 36 0 0.655 7 0 36 0 –
MEM 5 2 34 2 0.407 6 1 35 1 0.055
IMP 5 2 33 3 0.587 4 3 32 4 0.126
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in-patients were significantly higher compared to 
patients infected with carbapenem-sensitive strains (48 
and 20  %, respectively; p =  0.001). In this study, it was 
noted that receiving a transplant was an independent fac-
tor in carbapenem-resistant K. pneumoniae infection. In 
another study, the mortality rate was 60  % in a hetero-
geneous patient population that included carbapenem-
resistant K. Pneumoniae-infected transplant recipients 
[17]. In addition, staying in the ICU, surgical procedures, 
using catheter, length of hospitalization and using of 
cephalosporins and aminoglycosides are risk factors for 
carbapenem-resistant K. pneumoniae infections [18, 19].
In our study, sensitivity was determined using the auto-
mated VITEK®2 Compact system and the antimicrobial 
gradient test. Of the 43 strains, all were ertapenem-resist-
ant, 95.3  % were meropenem-resistant and 83.7  % were 
imipenem-resistant. A resistance rate of 97.7 % to ertape-
nem was detected using antimicrobial gradient test tech-
niques, whereas the resistance rate was 100 % according 
to the VITEK®2 automated system. Additionally, mero-
penem resistance was calculated using the antimicrobial 
gradient test (93 %) and the automated system (90.7 %).
The MHT is one of the simplest techniques used to 
indicate carbapenemase activity. In this test, carbapenem 
inhibition zone diameter and MIC values are considered 
sufficient [4] and valuable for the determination of KPC, 
OXA and MBL enzymes in laboratories in which dilution 
techniques cannot be performed [2, 20]. Herein, a cor-
relation was found between MHT technique results and 
OXA-48 gene positivity (p = 0.004) (Table 3). Raghuna-
than et  al. conducted studies in which they determined 
the carbapenem resistance of Enterobacteriaceae strains 
by comparing PCR and MHT techniques. The authors 
revealed a 96 % correlation between PCR positivity and 
MHT positivity in terms of KPC genes (causing carbap-
enem resistance) [21]. MHT is not sufficient to detect 
OXA-48 or other carbapenemase producing isolates. 
Combining carbapenemase inhibitor test, using phenylb-
oronic acid, with MHT is a good indicator fort the detec-
tion of carbapenemase producing isolates [22].
In the present study, the MBL antimicrobial gradient 
test was used to detect class B metallo-β-lactamases. Of 
the 43 isolates, MBL positivity was found in two. Of these 
two isolates, only one was NDM-1 positive according to 
PCR results. A correlation was observed between MBL 
antimicrobial gradient test results and NDM-1 positiv-
ity/negativity by multiplex PCR (Table 3). NDM-1 resist-
ance has been described in several case reports in recent 
years [14, 23]. However, class D OXA carbapenemase-
mediated carbapenem resistance has become prevalent, 
especially among Enterobacteriaceae strains causing 
nosocomial infections. In our country, an OXA-48 type 
β-lactamase belonging to class D carbapenemases was 
detected for the first time at the Istanbul University Fac-
ulty of Medicine Hospital. This carbapenemase enzyme 
was isolated from K. pneumoniae strains obtained from 
a urine culture of an in-patient [24]. The OXA-48 car-
bapenemase enzyme has mostly been identified in K. 
pneumoniae strains in Turkey, Lebanon and Belgium [14, 
25, 26]. Two studies evaluated carbapenem resistance in 
ESBL-producing carbapenem-resistant K. pneumoniae 
strains using disc diffusion and antimicrobial gradient 
test techniques [27, 28]. Of the 14 strains examined, the 
OXA-1 gene was detected in all, the OXA-48 gene in 
two, and the NDM-1 gene in two [27]. In addition, the 
IS1999 location was shown in strains expressing OXA-
48, indicating that ERT resistance was higher in OXA-
48 positive strains compared to other carbapenems [29]. 
According to studies performed in Greece and Spain, all 
carbapenem-resistant K. pneumoniae strains were posi-
tive for the OXA-48 gene. The OXA-48 gene was associ-
ated with the IS1999 element [30, 31]. In Turkey, the first 
NDM-1 resistance gene was identified in 2011 by Poirel 
et al. [14]. This gene was isolated from an allogeneic stem 
cell-transplanted leukemia patient from Iraq. From this 
isolated case, NDM-1 was identified as the first resist-
ance gene detected from an international origin [14]. 
Yanik et al. [12] conducted a study in Samsun-Turkey in 
which the carbapenemase enzyme was detected using 
the MHT technique in gram-negative strains resistant to 
at least one of the antibiotics (imipenem, meropenem or 
doripenem). PCR was performed to detect NDM-1, but 
no NDM-1 gene resistance was found in any of the 210 
clinical isolates. These results indicate that NDM-1 is 
not yet common in Turkey. The NDM-1 resistance gene 
with no history of foreign contacts was firstly determined 
by Alp et al. [23], in which 137 carbapenem-resistant K. 
pneumoniae strains were examined for resistance genes. 
Of 127 strains, OXA-48 was detected in 91.5 %, IMP in 
3.2  %, NDM-1 in 4.3  %, and both OXA-48 and NDM-1 
Table 3 Relationship between MHT and MBL E-test results 
with OXA-48 and NDM-1 genes positivity
MHT modifiye Hodge test, MBL E-test metallo-beta-lactamase E-test
Test Positive Negative p
n % n %
OXA-48
 MHT
  Positive 3 43 32 88.9 0.004
  Negative 4 57 4 11.1
NDM-1
 MBL E-test
  Positive 1 100 1 2.4 0.000
  Negative 0 0 41 97.6
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in 1 %. This study described herein has added Turkey to 
the list of countries in which NDM-1 has been isolated. 
According to our results, K. pneumoniae isolates were 
found to be NDM-1-positive (Table 3). This K. pneumo-
niae was isolated from a rectal swab of a patient who did 
not have any foreign origin.
It has been reported that carbapenem-producing 
Enterobactericeae strains lead to both infection and colo-
nisation, and these microorganisms cause nosocomial 
outbreaks as well as epidemics. Additionally, it is known 
that OXA carbapenemase-mediated carbapenem resist-
ance in particular is increasing [20]. Therefore, if there 
are high MIC values against carbapenems in Klebsiella 
strains, other accompanying resistance mechanisms 
should also be examined. In addition to phenotypic tests, 
genotypic investigations should be commonly used in 
order to decrease mortality and morbidity due to infec-
tions with Enteobactericeae spp.
Conclusion
The finding of one NDM-1-positive isolate in this study 
indicates that carbapenem resistance is spreading in Tur-
key. The finding of one NDM-1-positive isolate in this 
study indicates that carbapenem resistance is spread-
ing in Turkey. Carbapenem resistance spreads rapidly 
and causes challenges in treatment, and results in high 
mortality/morbidity rates. Therefore, is necessary to 
determine carbapenem resistance in Enterobacteriaceae 
isolates and to take essential infection control precau-
tions to avoid spread of this resistance.
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